The company recently closed on a Series A financing.
We established Animal Health Specialties LLC to commercialize our technology platform for applications in veterinary medicine and animal production.
Tensive Controls technology platform, protected by a family of patents and pending applications, allows us to modify peptides to perform better as drug candidates, with improved half-life, oral activity, and ability to cross the blood-brain barrier.
Tensive Controls Angiotensin (1-7) analog anti-tumor agent has been licensed and is in pre-clinical development. Our cancer cachexia drug candidate is completing pre-clinical development. Discovery programs are in progress with antimicrobial, anti-biofilm and antiviral peptides.
Tensive Controls was formed in 2009 to understand why melanocortin-based peptide drug candidates exhibit adverse cardiovascular side effects and to synthesize analogs free of such side effects as potential drug therapies for cancer cachexia.
One issued patent and four pending patents protect our technology platform.
The National Cancer Institute continues to fund our underpinning research in cancer cachexia.